NASDAQ:FULC - Fulcrum Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $17.86
  • Forecasted Upside: 48.69 %
  • Number of Analysts: 8
  • Breakdown:
  • 1 Sell Ratings
  • 1 Hold Ratings
  • 6 Buy Ratings
  • 0 Strong Buy Ratings
$12.01
▼ -0.49 (-3.92%)
1 month | 3 months | 12 months
Get New Fulcrum Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for FULC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for FULC

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$17.86
▲ +48.69% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Fulcrum Therapeutics in the last 3 months. The average price target is $17.86, with a high forecast of $23.00 and a low forecast of $11.00. The average price target represents a 48.69% upside from the last price of $12.01.
Buy
The current consensus among 8 contributing investment analysts is to buy stock in Fulcrum Therapeutics. This rating has held steady since October 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 1 sell ratings
9/12/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
12/11/2019
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
3/10/2020
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 1 sell ratings
6/8/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 1 sell ratings
9/6/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
12/5/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 1 sell ratings
2/3/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings
3/5/2021

Latest Recommendations

  • 0 strong buy ratings
  • 6 buy ratings
  • 1 hold ratings
  • 1 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
3/4/2021Piper SandlerLower Price TargetOverweight$22.00 ➝ $20.00High
i
3/1/2021Stifel NicolausInitiated CoverageBuy$18.00High
i
11/10/2020SVB LeerinkLower Price TargetOutperform$25.00 ➝ $23.00High
i
10/15/2020Piper SandlerInitiated CoverageOverweight$22.00Medium
i
8/12/2020BTIG ResearchLower Price Target$27.00 ➝ $22.00High
i
Rating by Dae Gon Ha at BTIG Research
8/12/2020Bank of AmericaDowngradeNeutral ➝ Underperform$11.00High
i
8/12/2020HC WainwrightLower Price TargetBuy$28.00 ➝ $20.00High
i
8/12/2020Morgan StanleyDowngradeOverweight ➝ Equal Weight$29.00 ➝ $11.00High
i
6/19/2020Bank of AmericaDowngradeBuy ➝ Neutral$19.00 ➝ $23.00High
i
6/17/2020Raymond JamesUpgradeMarket Perform ➝ OutperformHigh
i
6/16/2020BTIG ResearchInitiated CoverageBuy$27.00High
i
3/6/2020HC WainwrightReiterated RatingBuy$21.00 ➝ $28.00High
i
Rating by Andrew Fein at HC Wainwright
12/24/2019HC WainwrightReiterated RatingBuy$21.00Medium
i
Rating by Andrew Fein at HC Wainwright
10/3/2019HC WainwrightInitiated CoverageBuy$21.00High
i
Rating by A. Fein at HC Wainwright
8/12/2019SVB LeerinkReiterated RatingOutperformHigh
i
Rating by J. Schwartz at SVB Leerink LLC
8/12/2019Morgan StanleyInitiated CoverageOverweight$29.00High
i
8/12/2019Bank of AmericaInitiated CoverageBuy ➝ Buy$19.00High
i
(Data available from 3/6/2016 forward)
Fulcrum Therapeutics logo
Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment of facioscapulohumeral muscular dystrophy, a rare, progressive, and disabling muscle wasting disorder that leads to significant physical impairments and disability; and FTX-6058, a small molecule designed to upregulate fetal hemoglobin in patients with sickle cell disease and Ã-thalassemia. The company is also discovering drug targets for the treatments of duchenne muscular dystrophy, friedreich ataxia, myotonic dystrophy 1, and a-synucleinopathies, as well as neurological and pulmonary diseases. Fulcrum Therapeutics, Inc. has research and discovery collaboration agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and has a strategic collaboration and license agreement with MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was founded in 2015 and is headquartered in Cambridge, Massachusetts.
Read More

Today's Range

Now: $12.01
$11.82
$13.17

50 Day Range

MA: $12.82
$10.98
$15.32

52 Week Range

Now: $12.01
$7.01
$22.39

Volume

106,991 shs

Average Volume

161,850 shs

Market Capitalization

$392.33 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.94

Frequently Asked Questions

What sell-side analysts currently cover shares of Fulcrum Therapeutics?

The following Wall Street analysts have issued reports on Fulcrum Therapeutics in the last year: Bank of America Co., BTIG Research, HC Wainwright, Morgan Stanley, Piper Sandler, Raymond James, Stifel Nicolaus, SVB Leerink LLC, and Zacks Investment Research.
View the latest analyst ratings for FULC.

What is the current price target for Fulcrum Therapeutics?

7 Wall Street analysts have set twelve-month price targets for Fulcrum Therapeutics in the last year. Their average twelve-month price target is $17.86, suggesting a possible upside of 41.5%. SVB Leerink LLC has the highest price target set, predicting FULC will reach $23.00 in the next twelve months. Morgan Stanley has the lowest price target set, forecasting a price of $11.00 for Fulcrum Therapeutics in the next year.
View the latest price targets for FULC.

What is the current consensus analyst rating for Fulcrum Therapeutics?

Fulcrum Therapeutics currently has 1 sell rating, 1 hold rating and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe FULC will outperform the market and that investors should add to their positions of Fulcrum Therapeutics.
View the latest ratings for FULC.

What other companies compete with Fulcrum Therapeutics?

How do I contact Fulcrum Therapeutics' investor relations team?

Fulcrum Therapeutics' physical mailing address is 26 LANDSDOWNE STREET, CAMBRIDGE MA, 02139. The company's listed phone number is 617-651-8851 and its investor relations email address is [email protected] The official website for Fulcrum Therapeutics is www.fulcrumtx.com.